There are a number of things we're actually doing to study, in very practical terms, how we need to modernize. We recognize there's a big gap sitting there. A lot of the machinery we work with now in the regulations is 40 years old.
What's missing, the big gap, is really in the post-market. So as you mentioned, when we look at something pre-market, we're really looking in very ideal conditions at how the drug is behaving in very selected patients. It's when it gets out into the market that people might have other diseases that will affect taking the drug. They might be taking other drugs. That's where a lot of our new scientists are actually gathering. We need to pay attention to what other regulators in the world are doing. There are a lot of very good instruments we're studying there and trying to pull into the Canadian discussion.
We're also learning from Canadian patients. The people who use drugs chronically need a lot more information because they're with the drugs everyday. We need to understand their information needs when there's a risk with a product we might all take for a week and no more.
It's really an important study to us. We're trying to bring in as much as we can from the communities that use drugs, and make as few assumptions as possible. We've been conducting consultations for the last couple of years and really bringing people in at a very early stage to get a good solid evidence-based framework.